Panacea Biotec jumps as Karnataka declares dengue epidemic
The company revealed on August 14 that it has begun Phase-3 clinical trials for its Tetravalent Dengue Candidate Vaccine-DengiALL in India, following approval from the Drug Controller General of India (DCGI).
PANACEABIO
Steel
General
Markets